Neoadjuvant immunochemotherapy, in which a programmed cell death protein 1 inhibitor is combined with platinum-based chemotherapy before surgery, has transformed the outlook for locally advanced esophageal squamous cell carcinoma, the dominant histological subtype in China. Prospective trials such as ESCORT-Neo have demonstrated significantly improved pathological response and long-term survival. Yet the regimen exacts a heavy physiological toll. Even in highly selected trial cohorts, between 10.8 and 13.6 percent of patients never undergo surgical resection, with treatment-related adverse events and clinical intolerability contributing substantially to that attrition. Real-world evidence points to even harsher numbers, with severe toxicity affecting roughly 25 to 30 percent of patients and delaying or derailing planned operations. Because most prior analyses restricted themselves to patients who ultimately reached the operating table, early intolerance has remained a blind spot in the literature.

The research team, led from Fujian Medical University Union Hospital, addressed this gap by following every patient who initiated neoadjuvant therapy, not merely those who completed it. They introduced a novel framework called the neoadjuvant treatment tolerance grade, or NAT-TG, which integrates treatment intensity, dose reduction, delays, early discontinuation and completion of curative surgery into a single ordinal measure. Patients achieving full-intensity therapy followed by surgery were classified as NAT-TG1; those requiring modification but still reaching surgery were NAT-TG2; and those who failed to undergo curative surgery after starting treatment were NAT-TG3. This composite endpoint captures the entire neoadjuvant-to-surgery pathway, distinguishing physiological reserve from treatment feasibility in a way that conventional toxicity reporting does not.

The technical foundation of the study lies in imaging-based body composition analysis. Two trained radiologists, blinded to all clinical information and outcomes, independently selected an axial computed tomography image at the mid-pedicle level of the third lumbar vertebra, a standard landmark where skeletal muscle cross-sectional area correlates reliably with whole-body muscle mass. Using dedicated software, they segmented muscle tissue within attenuation thresholds of minus 29 to plus 150 Hounsfield units, manually correcting boundaries in roughly half of the cases to exclude misclassified adjacent structures. The resulting skeletal muscle area was normalized to height squared to yield the skeletal muscle index. Interobserver agreement was exceptional, with intraclass correlation coefficients of 0.994 for muscle area and 0.992 for the index, underscoring the reproducibility of the technique.

Rather than importing fixed cutoff values derived from Western populations, the investigators used X-tile software to derive sex-specific thresholds from their own cohort, defining low skeletal muscle index as less than 51.5 square centimeters per square meter in men and less than 37.5 in women. By this definition, 121 patients, or 26.2 percent of the cohort, had low muscle mass. Critically, most of these patients had a normal or even elevated body mass index, a phenomenon known as sarcopenic obesity or hidden muscle wasting. Body mass index, the researchers emphasize, cannot distinguish adipose tissue from lean mass, and patients with depleted muscle reserves hidden within an apparently adequate weight are precisely those most vulnerable to dose-limiting toxicity and premature treatment discontinuation.

The clinical consequences were stark. Only 48.8 percent of patients with low skeletal muscle index achieved the full-intensity treatment-and-surgery pathway, compared with 72.9 percent of those with preserved muscle. Unplanned failure to undergo curative surgery occurred in 20.7 percent of the low-muscle group versus 9.4 percent of the rest. Among the 57 patients who never reached the operating table, severe treatment-related toxicity was the dominant reason in 30 cases, persistent clinical or functional deterioration in 21, and disease progression in only six. Even after excluding the progression-related cases, low muscle mass remained independently associated with unfavorable tolerance, with an adjusted odds ratio of 2.51. Severe adverse events, particularly hematologic and gastrointestinal toxicities, were also markedly more frequent in the muscle-depleted group, affecting 36.4 percent versus 22.9 percent of patients.

Muscle depletion cast a long shadow beyond the neoadjuvant period. Among the 404 patients who underwent esophagectomy, those with low skeletal muscle index suffered severe postoperative complications, graded Clavien-Dindo III or higher, at nearly double the rate of their counterparts, 22.9 percent versus 11.0 percent, with pneumonia and pleural effusion driving much of the difference. After adjustment for age, sex, body mass index, serum albumin, operative approach, lymphadenectomy extent, tumor location and participating center, low muscle mass carried an adjusted odds ratio of 2.92 for severe surgical complications. Plausible mechanisms include reduced respiratory muscle strength, impaired cough effectiveness, altered drug distribution and clearance that increases systemic exposure to cytotoxic agents, and the chronic inflammation, metabolic dysregulation and immunosenescence that accompany muscle wasting, although the observational design cannot confirm direct causation.

Survival followed the same gradient. Over a median follow-up of 43 months, during which 165 deaths occurred, patients with low skeletal muscle index had a median overall survival of 35.0 months, while median survival had not been reached in the preserved-muscle group. Three-year overall survival was 49.4 percent with low muscle mass versus 74.4 percent without, and the association persisted across three progressively adjusted Cox models, with hazard ratios ranging from 2.17 to 2.38 in the intention-to-treat population. In the surgical cohort, low muscle mass independently predicted both poorer overall survival, with an adjusted hazard ratio of 1.91, and poorer disease-free survival, at 1.57. Bootstrap internal validation yielded optimism-corrected C-indices of approximately 0.68, indicating reasonably stable but moderate discrimination, and sensitivity analyses using published Prado and Fearon thresholds generally preserved the direction of the findings.

Perhaps the most provocative result emerged from an exploratory analysis of postoperative adjuvant immunotherapy. Among patients with low skeletal muscle index, those who received adjuvant immunotherapy within three months of surgery had substantially better three-year overall survival, 63.8 percent versus 43.1 percent, and disease-free survival, 59.0 percent versus 34.5 percent, compared with observation. The association survived multivariable adjustment, with adjusted hazard ratios of 0.47 for both death and recurrence or death, although a six-month landmark analysis designed to reduce immortal time bias produced estimates that crossed the null. No clear benefit was seen in patients with preserved muscle mass. The authors speculate that because muscle-depleted patients more often received modified or incomplete neoadjuvant therapy, they may carry greater residual disease burden, which postoperative immunotherapy could partially offset. They stress that this hypothesis-generating finding requires prospective validation.

The study has acknowledged limitations, including its retrospective design, potential residual confounding, cohort-derived cutoffs awaiting external validation, and the absence of muscle strength or physical performance measures, meaning the researchers assessed muscle quantity rather than clinically diagnosed sarcopenia. Nevertheless, the implications are considerable. The skeletal muscle index can be calculated from staging scans that esophageal cancer patients already undergo, at no additional cost or radiation exposure, offering a practical adjunct for baseline risk stratification. As immune checkpoint inhibitors and intensive multimodal regimens push treatment boundaries ever further, the study adds to mounting evidence that the body’s muscle compartment is not a passive bystander but an active determinant of who can endure, complete and benefit from modern cancer therapy, and that identifying hidden muscle depletion before treatment begins may open a window for nutritional and physical intervention.

Subject of Research: Skeletal muscle index as a predictor of tolerance and survival in neoadjuvant immunochemotherapy for oesophageal squamous cell carcinoma

Article Title: Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma

Article References: Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma. (n.d.). https://doi.org/10.1002/jcsm.70392

Image Credits: AI Generated

DOI: 10.1002/jcsm.70392

Keywords: skeletal muscle index, sarcopenia, oesophageal squamous cell carcinoma, neoadjuvant immunochemotherapy, body composition, PD-1 inhibitors, esophagectomy, treatment tolerance, postoperative complications, overall survival, CT imaging, adjuvant immunotherapy

The study, published in Cancer Immunology, Immunotherapy, evaluated sintilimab, a monoclonal antibody that blocks the programmed cell death protein 1, or PD-1, a molecular brake that tumors exploit to disable attacking immune cells. By releasing this brake, PD-1 inhibitors allow T cells to recognize and destroy cancer cells that would otherwise hide in plain sight. Sintilimab has already transformed the treatment landscape for several cancers in China, but its role in the post-surgical setting for esophageal cancer had remained largely uncharted territory.

The clinical problem the researchers tackled is a genuine one. While neoadjuvant therapy followed by esophagectomy has become a standard approach for locally advanced esophageal squamous cell carcinoma, many patients still harbor residual pathological disease after treatment, and others undergo upfront surgery only to be found with high-risk features such as deep tumor invasion or lymph node involvement. For these patients, evidence to guide adjuvant immunotherapy has been sparse. Most of the landmark immunotherapy trials in esophageal cancer focused on advanced, metastatic disease or on the neoadjuvant window before surgery, leaving the post-operative period as a therapeutic blind spot.

The trial, registered as ChiCTR2100049784, enrolled 32 patients between August 2021 and July 2023 at a single center. All had undergone R0 resection, meaning surgeons had removed the tumor with microscopically clear margins, the best achievable surgical outcome. Yet every patient carried high-risk pathology: either ypT1-4a and/or ypN+ disease after neoadjuvant therapy, or pT3-4 and/or pN+ disease after surgery performed first without pre-treatment. The majority, 27 patients or 84.4 percent, had received neoadjuvant therapy combining a PD-1 inhibitor with chemotherapy before their operation. Two patients, 6.3 percent, had neoadjuvant chemotherapy alone, and three patients, 9.4 percent, had undergone upfront surgery.

The treatment regimen was straightforward but demanding. Patients received sintilimab monotherapy every three weeks for up to 12 months, corresponding to 17 planned cycles. No chemotherapy or radiation was layered on top; the immunotherapy stood alone. The primary endpoint was the one-year recurrence-free survival rate, a prespecified benchmark the study needed to meet to be considered a success. Secondary endpoints included overall survival and safety, assessed throughout the treatment period and beyond.

The results exceeded expectations for a trial of this size. At a median follow-up of 47.0 months, nearly four years, the median recurrence-free survival had not been reached, meaning more than half of the patients had not experienced a recurrence by the time of analysis. The one-year recurrence-free survival rate stood at 87.5 percent, comfortably meeting the prespecified primary endpoint, while the two-year rate was 65.6 percent. Overall survival followed a similarly favorable trajectory: 93.8 percent of patients were alive at one year and 78.1 percent at two years, with median overall survival likewise not reached.

Safety data provided reassurance that the approach is tolerable. Treatment-related adverse events occurred in 13 patients, or 40.6 percent of the cohort, and grade 3 or higher events, the serious toxicities that can threaten organ function or require hospitalization, appeared in 7 patients, or 21.9 percent. Critically, no treatment-related deaths occurred, a notable finding given that immune checkpoint inhibitors can occasionally trigger severe immune-mediated inflammation in organs such as the lungs, liver, colon, or endocrine glands. Despite the manageable safety profile, adherence to the full course was imperfect: 17 patients, or 53.1 percent, completed all 17 planned cycles, a completion rate that reflects the real-world challenges of maintaining a year-long treatment, whether due to adverse events, recurrence, or patient choice.

The immunological rationale underlying these findings deserves attention. Neoadjuvant chemoradiation or chemoimmunotherapy can prime the immune system by releasing tumor antigens as cancer cells die, creating a window of heightened immune surveillance. Administering a PD-1 inhibitor in the adjuvant setting may then consolidate that priming, helping circulating and tissue-resident T cells eliminate microscopic residual disease before it can establish clinically detectable metastases. The strong showing of the 87.5 percent one-year recurrence-free survival rate in a cohort overwhelmingly composed of patients treated with neoadjuvant PD-1 blockade plus chemotherapy suggests that the perioperative sequencing of immunotherapy, before and after surgery, may act synergistically, though the single-arm design cannot formally disentangle the contributions of each component.

The authors and independent observers alike caution that the study’s design imposes limits on interpretation. With no control arm, it is impossible to say with certainty how patients would have fared with observation alone or with alternative adjuvant strategies, and the single-center enrollment of 32 patients means the confidence intervals around the survival estimates are wide. Selection factors, including the general fitness required to undergo esophagectomy and then a year of immunotherapy, may also inflate outcomes relative to the broader population of high-risk patients. The researchers themselves state that the findings support further evaluation in larger randomized controlled trials with longer follow-up, and the field is watching ongoing perioperative immunotherapy studies in esophageal cancer that may soon provide the randomized evidence needed to change guidelines.

Even with those caveats, the trial adds an important piece to a rapidly evolving puzzle. Esophageal squamous cell carcinoma remains one of the most lethal malignancies worldwide, with five-year survival historically languishing in the double digits even after curative-intent surgery. The demonstration that adjuvant sintilimab monotherapy met its prespecified efficacy endpoint with manageable toxicity and no treatment-related deaths provides a template for how post-operative immunotherapy could be integrated into multimodal treatment programs. If larger randomized trials confirm these results, the standard of care for high-risk resected esophageal cancer could shift from watchful waiting after surgery to a full perioperative immunotherapy strategy, turning a period of anxious uncertainty into an active, immune-based defense against recurrence.

Subject of Research: Adjuvant PD-1 inhibitor therapy for high-risk resected esophageal squamous cell carcinoma

Article Title: Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial

Article References: Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial. (n.d.). https://doi.org/10.1007/s00262-026-04579-6

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04579-6

Keywords: esophageal squamous cell carcinoma, sintilimab, PD-1 inhibitor, adjuvant immunotherapy, recurrence-free survival, phase II trial, esophagectomy, cancer immunotherapy, neoadjuvant therapy, overall survival, treatment-related adverse events, Peking University Cancer Hospital